Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Aortic Stenosis Patients Undergoing Aortic Valve Replacement
NCT06171802Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in aortic valve stenosis comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in left ventricular mass indexed to body surface area at 6 months. Started Feb 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
aortic valve stenosis
Beyond the preview
Go deeper on NCT06171802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171802.